Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05761899 · ClinicalTrials.gov registry record · Phase 1

Safety and Efficacy of PMT Therapy of hPAP

A Phase 1 study of Hereditary Pulmonary Alveolar Proteinosis, sponsored by Children's Hospital Medical Center, Cincinnati.

Recruiting
Registry status
Phase 1
Development phase
3
Enrollment target
1
Study location

NCT05761899 is a Phase 1 study of Hereditary Pulmonary Alveolar Proteinosis that is actively recruiting participants, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 3 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05761899, a Phase 1 study of Hereditary Pulmonary Alveolar Proteinosis, is actively recruiting participants, sponsored by Children's Hospital Medical Center, Cincinnati.

RECRUITING
Registry status
Phase 1
Development phase
3 participants
Enrollment target
1
Study location

Study Summary

The major goal of this study is to evaluate a new type of cell transplantation therapy for individuals with hereditary PAP, study a new treatment that may be useful for treatment of other diseases, and research mechanisms that drive the development and function of lung macrophages.

Interventions

  • COMBINATION_PRODUCT Gene-Corrected Macrophages administered by bronchoscopic instillation

Study Locations (1)

Ohio

  • Cincinnati Children's Hospital Medical Center - Cincinnati

Trial Details

FieldValue
Enrollment Target 3 participants
Start Date 2023-06-26
Est. Completion 2038-10-01
Phase Phase 1

What the Registry Record Tells You About NCT05761899

The ClinicalTrials.gov registry entry for NCT05761899 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Hospital Medical Center, Cincinnati, which has 571 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hereditary Pulmonary Alveolar Proteinosis appearing as the primary indexed condition, and to 1 intervention - of which Gene-Corrected Macrophages administered by bronchoscopic instillation is the first listed.

NCT05761899 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT05761899 about?

NCT05761899 is a clinical study titled "Safety and Efficacy of PMT Therapy of hPAP". The major goal of this study is to evaluate a new type of cell transplantation therapy for individuals with hereditary PAP, study a new treatment that may be useful for treatment of other diseases, and research mechanisms that drive the development and function of lung macrophages.

What is the current status of trial NCT05761899?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2023-06-26. Estimated completion is 2038-10-01.

What conditions does trial NCT05761899 study?

This clinical trial studies the following conditions: Hereditary Pulmonary Alveolar Proteinosis.

What interventions are being tested in trial NCT05761899?

The interventions under investigation include: Gene-Corrected Macrophages administered by bronchoscopic instillation (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT05761899?

This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05761899 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.